ArticleEcancermedicalscience2026
Treatment outcomes of paediatric chest wall Ewing's sarcoma; report from tertiary care cancer center.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chest wall Ewing sarcoma (EWS) is a common paediatric malignant tumour affecting the chest wall, accounting for about 10% of all EWS patients. Treatment typically involves intense chemotherapy, complete surgical resection when possible and/or radiation. The EWS of the chest wall has a reported 5-year survival ranging between 40% and 60% in most studies. The following study evaluated the effect of different treatment modalities on survival outcomes in paediatric patients. Methodology: This is a single-center retrospective cohort study that included 46 patients diagnosed with chest wall EWS between January 2011 and December 2023 at Shaukat Khanum Memorial Cancer Hospital and Research Center. Approval was obtained from the Institutional Review Board for this study. The 5-year follow up period and outcomes were analysed using the SPSS. Results: The cohort included 46 patients (56% female, 44% male) with a median age of 10 years. Non-metastatic disease was observed in 94% of the patients. The compressed vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide chemotherapy regimen showed better outcomes, with a 48% survival rate compared with 38% for vincristine, doxorubicin, actinomycin, ifosfamide and etoposide. Negative surgical margins were associated with a 56% survival rate. 5-year overall survival (OS) of 42.5% and event-free survival (EFS) of 39%. Both the OS and EFS were better in patients who had surgery alone as local control (LC). Conclusion: Outcomes in patients who had surgery as LC did better in this study. Early recognition and referral may help in reducing the tumour burden so that good LC with surgical R-zero resection is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.